SCHEMBL4868252

SCHEMBL4868252

Cc1cc(O)ccc1NC(=O)N1CCCCc2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
USP2 O75604 1/20 0.57
POLB P06746 2/20 0.56
LMNA P02545 4/20 0.56
TP53 P04637 3/20 0.56
MAPT P10636 2/20 0.55
NPC1 O15118 2/20 0.53
NFKB1 P19838 2/20 0.53
RAB9A P51151 2/20 0.53
NFKB2 Q00653 2/20 0.53
RELA Q04206 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PKM P14618 1/20 0.53
MAPK1 P28482 2/20 0.52
ALDH1A1 P00352 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867648 0.91 TP53 (0.48) MEN1KMT2AUSP2POLBLMNA
SCHEMBL14089573 0.87 MEN1 (0.62) MEN1KMT2AUSP2POLBLMNA
SCHEMBL4871226 0.86 CHRM2 (0.61) MEN1KMT2AUSP2POLBLMNA
SCHEMBL4870081 0.86 LMNA (0.53) MEN1KMT2AUSP2LMNATP53
SCHEMBL4867240 0.85 MEN1 (0.66) MEN1KMT2AUSP2LMNATP53
SCHEMBL4870691 0.84 PDK1 (0.58) MEN1KMT2ALMNATP53MAPT
SCHEMBL4863076 0.83 MAPT (0.69) MEN1KMT2APOLBLMNATP53
SCHEMBL4860527 0.82 ATM (0.57) MEN1KMT2AUSP2LMNAMAPT
SCHEMBL4867674 0.82 MEN1 (0.56) MEN1KMT2AUSP2POLBLMNA
SCHEMBL4871151 0.82 MAPT (0.67) MEN1KMT2APOLBLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MEN1 651/4885KMT2A 2577/4885USP2 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.